Loading
Latest filing published 22 Jun 2016 for Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation), €1,444.
Tom Rossi is a declared insider of Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation), with filings sourced from SEDI. Altogether 2 filings, all relating to 21 June 2016.
The open-market record is one-sided, with 2 purchases worth €10k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
The record was last updated on 22 June 2016 with an open-market purchase (€1,444) in Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation). Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.